News overview
News
31 March 2023
Oncode Clinical Proof of Concept funded International Leukemia Target Board (iLTB) is now ready for its next steps
Oncode Investigator Monique den Boer, in collaboration with Judith Boer, Uri Ilan and the team of the trial and data center (headed by Michel Zwaan of the Princess Máxima Center) initiated the International Leukemia Target Board (iLTB). From its start, the initiative was funded through Oncode’s Clinical Proof of Concept (CPoC) programme. The base-laying set-up of the project is now finalized, and with the additional funding it has received, it is ready to continue into its execution phase.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
17 March 2023
New study Sjoerd van der Burg Lab on underlying mechanisms in immunotherapy resistance
A new study from the lab of Oncode Investigator Sjoerd van der Burg (LUMC) was published in the Journal for ImmunoTherapy of Cancer (JITC) this week. The study focuses on understanding why some cancer treatments that use the body's immune system (immunotherapy) don't work as well as they should.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
16 March 2023
Cyclomics starts new research collaboration with Oxford Nanopore Technologies
Research collaboration has resulted in new ‘liquid biopsy’ research workflow using nanopore sequencing to detect molecules that are associated with cancer, circulating in blood. Cyclomics is an UMC Utrecht spinoff company, co-founded by Oncode Investigator Jeroen de Ridder. Cyclomics obtained initial funding via the Oncode Bridge Fund.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
7 March 2023
Hugo Snippert wins 2023 Ammodo Science Award for fundamental research
Oncode Investigator Hugo Snippert (UMCU) won the prestigious Ammodo Science Award for fundamental research 2023. He is one of the eight selected scientists selected from across four scientific domains, receiving a cash prize of 350.000 euros, which he can use in the coming years to explore new avenues of fundamental scientific research.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
3 March 2023
Oncode Investigators Tineke Lenstra and Jurgen Marteijn receive ENW-M collaborative grant
Oncode Investigators Tineke Lenstra (NKI) and Jurgen Marteijn (Erasmus MC) have been awarded an ENW-M collaborative grant by the Dutch Research Council (NWO). The ENW-M grants are intended for curiosity driven scientific research with impact. In this collaboration, they aim to understand what happens with Pol II and transcription when Pol II stalls at DNA damage sites.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
2 March 2023
DNA testing predicts ineffective chemotherapy treatment for colon cancer patients
Oncode Investigator Emile Voest and Oncode researcher Joris van de Haar (both NKI) have shown how by using a DNA test, it is possible to predict which patients with metastatic colon cancer will not benefit from the life-extending chemotherapy regimen FTD/TPI. The results are now published in Nature Medicine.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
In the spotlight
25 April 2022
Interview on Oncode-PACT: De-risking the preclinical phase
Although Dutch fundamental cancer research is among the world’s best, findings in this area rarely result in viable cancer medicines. How should this be improved? Oncode’s Managing Director Alain Kummer, Oncode Business Development expert Emil Pot and Friso Smit, business development manager of the Utrecht Science Park, reflect on this issue, with reference to the Oncode-PACT* Growth Fund proposal. They co-created this proposal with many other stakeholders.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
23 February 2023
New EU-funded Project: Fragment-Screen
The aim of Fragment-Screen, a new Horizon Europe project, is to develop innovative instrumentation, workflows, and experimental and computational methodologies to accelerate the development of new drugs using the approach of fragment-based drug discovery (FBDD). This will be relevant for the Oncode Institute and Oncode-PACT communities.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
21 February 2023
Unexpected side effect sabotages immunotherapy
Oncode Investigator Daniel Peeper and his team at the NKI discovered an unexpected effect of a new type of immunotherapy. This may explain why this therapy proved ineffective in the final phase of clinical research. The findings are now published in Cell Reports Medicine.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
9 February 2023
Follow-up funding for Oncode Institute to keep cracking the code of cancer
Oncode Institute is very proud to announce that we will continue for another 5 years. We would like to thank our vibrant research community for all their hard work and look forward to working together.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
6 February 2023
UNCAN.EU survey: identify the next challenges in cancer research!
One of UNCAN.EU’s tasks is to evaluate scientific literacy and perception of the importance of cancer research. Filling the online survey the initiative has recently launched will contribute to that, and will help identify the next research challenges from the side of cancer patients & survivors, caregivers, and the general public.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
Scroll for more